https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0028
Announcing a new article publication for
Cardiovascular Innovations and Applications journal. A new real-world analysis using data from the Tianjin Health and Medical Big Data Super Platform provides the first large-scale clinical insights from Asia into anticoagulation practices for patients with acute myocardial infarction (AMI) and preexisting atrial fibrillation (AF), a population known to be at heightened risk for adverse cardiovascular events.
This study addresses a critical evidence gap regarding the contemporary use of direct oral anticoagulants alongside antiplatelet therapy, revealing that rivaroxaban is prescribed in combination therapy in 18.7% of Chinese patients with AMI and AF. The findings show that rivaroxaban use is associated with a reduced risk of stroke without an accompanying increase in bleeding events, offering new evidence to inform clinical decision-making for this high-risk population.
# # # # # #
CVIA is available on the
ScienceOpen platform and at
Cardiovascular Innovations and Applications. Submissions may be made using
ScholarOne Manuscripts. There are no author submission or article processing fees.
Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow
CVIA on Twitter
@CVIA_Journal; or
Facebook.
Ying Liu, Yi Zheng and Gregory Y. H. Lip et al. Effects of Rivaroxaban on Prognosis in Patients with Acute Myocardial Infarction and Preexisting Atrial Fibrillation.
CVIA. 2025. Vol. 10(1). DOI: 10.15212/CVIA.2025.0028